Brief: Abliva Reports Completion Of Kl1333 Phase 1A/B Study

Abliva AB

16/03/2021 13:46

March 16 (Reuters) - Abliva AB  ABLI.ST :
    * ABLIVA REPORTS COMPLETION OF KL1333 PHASE 1A/B STUDY
    * ABLIVA AB - NO SERIOUS ADVERSE EVENTS (SAES) HAVE BEEN REPORTED, AND STUDY DATA WILL BE
EVALUATED DURING SPRING AND EARLY SUMMER.
    * ABLIVA AB - ABLIVA PLANS TO START A REGISTRATIONAL CLINICAL PHASE 2/3 EFFICACY STUDY
DURING
SECOND HALF OF 2021.

Source text for Eikon:  ID:nMFN6n2lR9 
Further company coverage:  ABLI.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))